Fig. 3From: Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trialKaplan–Meier curves for A second disease progression, B time to chemotherapy, and C chemotherapy-free survival in the premenopausal population of the MONARCH 2 trial. CI, confidence interval; HR, hazard ratioBack to article page